<DOC>
	<DOCNO>NCT02407600</DOCNO>
	<brief_summary>This study evaluate addition fosaprepitant currently available antiemtic treatment carboplatin chemotherapy-induced nausea vomit advanced non-small cell lung cancer patient . Half patient receive fosaprepitant first chemotherapy cycle , placebo second chemotherapy cycle . The half patient begin first chemotherapy cycle .</brief_summary>
	<brief_title>Study Assessing Fosaprepitant Advanced NSCLC Patients Treated With Carboplatin Based Chemotherapy</brief_title>
	<detailed_description>The addition aprepitant 5HT-3 antagonist steroid approve prevention acute delay nausea highly emetogenic chemotherapy ( HEC ) . The use oral aprepitant 3 day regimen evaluate moderately emetogenic chemotherapy . However , use explore carboplatin contain combination regimen advance non-small cell lung cancer ( NSCLC ) . An equivalency study compare fosaprepitant , 1-day intravenous formulation aprepitant , oral aprepitant . Findings demonstrate equivalence agent complete response emesis nausea control . Fosaprepitant endorse ASCO Update Committee acceptable NK1 receptor antagonist . However , evaluation iv formulation moderately emetogenic chemotherapy specifically carboplatin contain regimen NSCLC . Therefore , investigator propose double-blind , randomize placebo control cross-over phase II study assess role fosaprepitant prevention nausea emesis patient receive carboplatin base chemotherapy advance NSCLC . Patients treat Emend/ placebo administer intravenously day 1 cycle 1 carboplatin base chemotherapy crossover alternate agent ( placebo/ Emend ) day 1 cycle 2 cycle 21 day . Fosaprepitant administer intravenously day 1 either cycle 1 cycle 2 prior carboplatin base chemotherapy . Placebo administer alternative agent . Study team subject blind fosaprepitant versus placebo .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<criteria>Patient age &gt; 18 year able sign inform consent . ECOG PS 02 Patients stage IV recurrent NSCLC treat carboplatin base regimen palliative intent . Acceptable chemotherapy regimen include : Carboplatin ( AUC 5 OR 6 ) q 21 day : Paclitaxel Q 21 day OR Docetaxel Q 21 day OR Pemetrexed Q 21 day ( nonsquamous histology Vitamin B12 folate supplementation ) OR Gemcitabine administer day 1 8 Q 21 day OR Vinorelbine administer day 1 8 Q 21 day The addition bevacizumab chemotherapy permit indicate clinically appropriate . Patients receive prior adjuvant chemotherapy lung cancer ( &gt; 1 year prior ) recur eligible &gt; 1 year since completion adjuvant chemotherapy . Patients treat locally advanced lung cancer concurrent chemoradiation complete therapy &gt; 1 year ago eligible provide meet inclusion criterion . Patients receive prior adjuvant chemotherapy lung cancer ( &gt; 1 year prior ) recur eligible &gt; 1 year since completion adjuvant chemotherapy . Patients treat locally advanced lung cancer concurrent chemoradiation complete therapy &gt; 1 year ago eligible provide meet inclusion criterion . Laboratory parameter : Serum creatinine &lt; 2.0 AST , ALT &lt; 3 time upper limit normal Platelet count ≥ 100,00/cumm ANC ≥ 1500/ cumm day therapy ( day # 1 cycle ) Hemoglobin &gt; 8.0 g/dl History allergic reaction aprepitant fosaprepitant Use investigational agent concurrently chemotherapy Uncontrolled systemic hypertension SBP &gt; 180 and/ DBP &gt; 110 Concurrent use pimozide , terfenadine , astemizole , cisapride ( fosaprepitatnt dosedependent inhibitor cytochrome P450 isoenzyme 3A4 ( CYP3A4 ) . If use concurrently agent , elevate plasma concentration drug , potentially cause serious lifethreatening reaction . Patients may enrol study least 7 day elapse since last dose medication . Women pregnant lactate eligible . Women childbearing age musthave negative pregnancy test within 3 day treatment agree use contraception study period . Use CYP450 inducer like phenytoin , carbamazepine , barbiturate , rifimapicin , rifabutin St John 's wort within 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>EMEND Injection</keyword>
	<keyword>5HT-3</keyword>
	<keyword>Fosaprepitant</keyword>
</DOC>